Abstract: The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a solution of pre-formed lipid nanoparticles and mRNA.

Abstract: The present invention is directed to new stable immediate release tablet and capsule formulations for the Janus Kinase 3 (JAK3) inhibitor 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one para-toluenesulfonate having structure

Abstract: Cosmetic and dermatological compositions, including color changing compositions, are provided which typically include a plurality of synthetic particles having a size in the micrometer or nanometer range. The cosmetic or dermatological formulation comprises an antioxidant or UV filter and xanthommatin pigment present in the formulation at a concentration of 0.01% wt to 0.5% wt to scavenge free radicals. The cosmetic or dermatological formulation can be a sun protectant composition having an SPF of 2-30.

Abstract: A scaffold composite, and a preparation method and use thereof are provided. The preparation method includes: mixing a graphene oxide (GO) dispersion and a polylactic acid (PLA) dispersion, and subjecting a resulting mixed solution to curing and melt extrusion in sequence to obtain a 3-dimensional (3D)-printable GO/PLA composite wire; subjecting the 3D-printable GO/PLA composite wire to 3D printing to obtain a scaffold; and annealing the scaffold to obtain the scaffold composite.

Abstract: Provided is a toroidal mixed nanoparticle including a first polymer and a second polymer interacting with the first polymer. Also provided is a method for preparing the toroidal mixed nanoparticle, including mixing the first polymer and the second polymer having cleavable hydrophobic groups to form a mixed nanoparticle; and removing a portion of cleavable hydrophobic groups from the second polymer to make the second polymer charged and to form the toroidal mixed nanoparticle. Further provided is a method for delivering a drug or a bioactive agent to a subject in need thereof, including administering to the subject a pharmaceutical composition that includes the toroidal mixed nanoparticle conjugated to an effective amount of the drug or the bioactive agent, and a pharmaceutically acceptable excipient thereof.

Abstract: Provided are powder of a pure disilver hydrogen citrate-containing composition in powder form, having excellent solubility, and a method for easily obtaining the disilver hydrogen citrate-containing composition with high efficiency. In addition, provided are an antibacterial agent or antiviral agent, containing the disilver hydrogen citrate-containing composition, and a method for producing the same. The method for producing a disilver hydrogen citrate-containing composition of the present invention includes the following processes (1) to (3): (1) preparing a reaction mixture containing a silver compound and citric acid, the reaction mixture having a pH of 2.0 to 5.5; (2) precipitating the disilver hydrogen citrate-containing composition from the reaction mixture; and (3) collecting the precipitated disilver hydrogen citrate-containing composition.

Abstract: The present specification discloses a composition comprising, consisting essentially of, or consisting of hypochlorous acid or free available chlorine in combination with one or more metallic particles, one or more metal salts, or any combination thereof. The present specification further discloses a kit comprising, consisting essentially of, or consisting of a one or more containers including a composition disclosed herein or components which make up such compositions as well as methods and uses for such compositions and kits.

Abstract: Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally, provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.

Abstract: Storage stable aqueous ready-to-administer formulations comprising isoproterenol are presented with desirable stability characteristics. In preferred aspects, formulations are terminally sterilized and packaged in a suitable format, such as a polymeric bag with metalized overwrap and include a non-contact oxygen scavenger.

Abstract: Cosmetic and dermatological compositions, including color changing compositions, are provided which typically include a plurality of synthetic particles having a size in the micrometer or nanometer range. Each synthetic particle typically includes one or more aggregates of a pigment selected from phenoxazone, phenoxazine, and a derivate or precursor thereof, and a stabilizing material which has a refractive index larger than 1.45; the aggregates having a size larger than about 100 nm and the composition being biodegradable and biocompatible.

Abstract: A cosmetic composition is provided. The cosmetic composition comprises a carboxylic acid modified silicone (A) that has a specific chemical structure and is liquid at room temperature. The cosmetic composition also comprises an oil agent (B). The cosmetic composition generally provides a cosmetic film having excellent water resistance, and can be easily removed by normal soap and water.

Abstract: A method of treatment or prevention of HIV and other viral infection comprising the administration of a biopolymer-based hydrogel nanoparticles and/or microparticles. In preferred embodiments, the particles comprise chitosan, hydroxyethyl cellulose (HEC), and linseed oil polyol. These biopolymer-based hydrogel nanoparticles and/or microparticles are antiviral agents that can be employed alone or in combination with other drugs for treatment of the viral infection. Further, the pre-treatment with the particles is highly effective at inhibiting viruses. Therefore, this antiviral biopolymer-based hydrogel nanoparticles and/or microparticles may also be employed as a prophylactic.

Abstract: Implantable drug delivery devices include a housing defining a reservoir, a first unit within the reservoir, and a second unit within the reservoir. The first unit contains a drug and the second unit contains a functional agent that facilitates release of the drug. Intravesical drug delivery devices include a housing portion containing a drug formulation and a housing portion containing an excipient, and are configured to release the drug according to a first release profile and the excipient according to a second release profile. Methods include inserting any of these devices into a patient and releasing drug from the device.

Abstract: A working disinfectant solution comprising peracetic acid and at least one surfactant, prepared by the dilution of either a single-part or two-part concentrate for use in the disinfection or sterilisation of reusable medical devices such as endoscopes. The working solution exhibits rapid wetting characterised by a dynamic surface tension of less than 50 mN/m at 250 ms and 46 mN/m at 500 ms.

Abstract: The devices, systems, and methods disclosed herein may be directed to a delivery system including a therapeutic member configured for endoluminal placement via the delivery system into the esophagus of the patient, wherein the therapeutic member comprises a treatment portion comprising a film for controlled release of a chemotherapeutic agent. The film may comprise a control region, a therapeutic region, and a substantially impermeable base region. The film is configured to release the chemotherapeutic agent in a direction away from the substantially impermeable base region. The delivery system is configured to enable a treatment provider to position the treatment portion of the therapeutic member proximate to a treatment site associated with the esophagus of the patient, and the therapeutic member is configured to administer a therapeutically effective dose to the treatment site for a sustained period following endoluminal placement of the therapeutic member.

Abstract: The solid preparation which improved the dissolution profile and the stability of the 6,7-unsaturation-7-carbamoyl morphinan derivative is provided. When 6,7-unsaturation-7-carbamoyl morphinan derivative, croscarmellose sodium and ferric oxide were contained, not titanium oxide in the solid preparations and the coating solid preparations, a dissolution rate after 15 minutes of the dissolution test is more than 85%, and stability, particularly, light stability can be improve.

Abstract: The invention relates to fast-acting viricidal compositions and methods of using the same, wherein the compositions are capable of removing soil and effectively inactivating a wide variety of viral pathogens, particularly small, non-enveloped viruses such as poliovirus and norovirus. The compositions are especially useful on hard surfaces, and can easily be applied to a service to provide rapid viricidal efficacy.

Abstract: An object of the present invention is to provide a spraying agent containing a pesticide having a higher pesticidal effect. The spraying agent of the embodiment of the present invention is characterized by being an aqueous solution containing, as the pesticide, boric acid that acts as a food poison for pests (for example, red mites) and an alkali metal silicate that acts as a spiracle barrier and a migration suppressor for pests, and further containing at least one of a protein and a carbohydrate for acting to attract or feed the pests, and an emulsifier or a surfactant and a fat and oil having an effect of removing the oil or fat on the epidermis of the pests.

Abstract: Provided herein is a compound which is particularly suitable for use as a cannabinoid, as an emulsifier for a cannabinoid, in a formulation comprising the compound and in a method of treatment using the compound. The compound is defined by the General Formula: wherein: R1-R10 are independently selected from H or an alkyl of 1-10 carbons; alkenyl of up to 10 carbons; or groups on adjacent carbons may be taken together to form an alkene; R11 and R12 are independently H or —(CH2CHR16O)x—R17 with the proviso that at least one of R11 or R12 represents —(CH2CHR16O)xR17—; R11 and R10 may be taken together to represent —C(R19)2—; R13-R15 independently represent H or an alkyl of 1-8 carbons; each R16 independently represents H or an alkyl of 1-3 carbons; each R17 independently represents H, an alkyl or substituted alkyl of 1-22 carbons, aryl or substituted aryl or the ester of an acid; each R19 independently represents H or an alkyl of 1-5 carbons; and each x is independently an integer of 1-100.

Abstract: A method of treatment or prevention of HIV and other viral infection comprising the administration of a biopolymer-based hydrogel nanoparticles and/or microparticles. In preferred embodiments, the particles comprise chitosan, hydroxyethyl cellulose (HEC), and linseed oil polyol. These biopolymer-based hydrogel nanoparticles and/or microparticles are antiviral agents that can be employed alone or in combination with other drugs for treatment of the viral infection. Further, the pre-treatment with the particles is highly effective at inhibiting viruses. Therefore, this antiviral biopolymer-based hydrogel nanoparticles and/or microparticles may also be employed as a prophylactic.